Kyntra Bio (KYNB) Income from Discontinued Operations (2024)
Kyntra Bio (KYNB) posted Income from Discontinued Operations of 85000.0 for Q4 2024, up 844.44% sequentially from 9000.0 in Q3 2024.
Kyntra Bio (KYNB) Income from Discontinued Operations (2024) Analysis & Trends
Kyntra Bio has reported Income from Discontinued Operations for 1 years, with the latest figure at 85000.0 in Q4 2024.
- Quarterly Income from Discontinued Operations changed N/A year-over-year to 85000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 85000.0 (changed N/A YoY) and the FY2024 annual result came in at 139000.0, down 45.49% from the prior year.
- Income from Discontinued Operations grew to 85000.0 in Q4 2024 per KYNB's latest filing, from 9000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at 85000.0 in Q4 2024 and troughed at 9000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 85,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 26,000.00 |